Market Overview

JMP Securities Upgrades Infinity Pharmaceuticals To Market Outperform


Analysts at JMP Securities upgraded Infinity Pharmaceuticals (NASDAQ: INFI) from Market Perform to Market Outperform.

The target price for Infinity Pharmaceuticals is set to $24.

Infinity Pharmaceuticals shares have dropped 22.09% over the past 52 weeks, while the S&P 500 index has gained 20.88% in the same period.

Infinity Pharmaceuticals' shares jumped 44.05% to close at $15.73 yesterday.

Latest Ratings for INFI

Jan 2019B. Riley FBRInitiates Coverage OnBuy
Nov 2018Wells FargoDowngradesOutperformMarket Perform
Nov 2018JP MorganDowngradesNeutralUnderweight

View More Analyst Ratings for INFI
View the Latest Analyst Ratings

Posted-In: JMP SecuritiesUpgrades Analyst Ratings


Related Articles (INFI)

View Comments and Join the Discussion!

Latest Ratings

PLXSSidoti & Co.Initiates Coverage On0.0
TIFBank of AmericaReiterates104.0
MOBank of AmericaReiterates66.0
FDXBank of AmericaReiterates188.0
AUPHRaymond JamesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Trader Essentials
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

Mattress Firm To Fund Sleep Train Acquisition Cash Portion With Cash Reserves

UPDATE: Joy Global Q3 Profit Misses Estimates, Shares Drop